How to buy Verrica Pharmaceuticals stock (VRCA)

Verrica Pharmaceuticals is a biotechnology business based in the US. Verrica Pharmaceuticals shares (VRCA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.68 – a decrease of 1.44% over the previous week. Verrica Pharmaceuticals employs 100 staff and has a trailing 12-month revenue of around $9.2 million.

Our top picks for where to buy Verrica Pharmaceuticals stock

Buy Verrica Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Verrica Pharmaceuticals stock price (NASDAQ: VRCA)

Use our graph to track the performance of VRCA stocks over time.

Verrica Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.68
52-week range	$0.61 - $11.41
50-day moving average more info button	$1.09
200-day moving average more info button	$4.53
Wall St. target price	$6.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.84

Is it a good time to buy Verrica Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Verrica Pharmaceuticals price performance over time

Historical closes compared with the close of $0.649 from 2024-12-26

1 week (2024-12-20)	-6.48%
1 month (2024-11-27)	-47.66%
3 months (2024-09-27)	-61.60%
6 months (2024-06-27)	-91.01%

1 year (2023-12-27)	-90.92%
2 years (2022-12-27)	-73.72%
3 years (2021-12-27)	9.49
5 years (2019-12-27)	15.88

Verrica Pharmaceuticals financials

Revenue TTM	$9.2 million
Operating margin TTM	1162.49%
Gross profit TTM	$8.3 million
Return on assets TTM	-71.41%
Return on equity TTM	-2059.89%
Profit margin	0%
Book value	$-0.75
Market Capitalization more info button	$58.7 million

TTM: trailing 12 months

Verrica Pharmaceuticals share dividends

We're not expecting Verrica Pharmaceuticals to pay a dividend over the next 12 months.

Verrica Pharmaceuticals share price volatility

Over the last 12 months, Verrica Pharmaceuticals's shares have ranged in value from as little as $0.611 up to $11.41. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verrica Pharmaceuticals's is 1.457. This would suggest that Verrica Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Verrica Pharmaceuticals overview

Verrica Pharmaceuticals Inc. , a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co. , Ltd.

Frequently asked questions

What percentage of Verrica Pharmaceuticals is owned by insiders or institutions?
Currently 43.855% of Verrica Pharmaceuticals shares are held by insiders and 15.802% by institutions. How many people work for Verrica Pharmaceuticals?
Latest data suggests 100 work at Verrica Pharmaceuticals. When does the fiscal year end for Verrica Pharmaceuticals?
Verrica Pharmaceuticals's fiscal year ends in December. Where is Verrica Pharmaceuticals based?
Verrica Pharmaceuticals's address is: 44 West Gay Street, West Chester, PA, United States, 19380 What is Verrica Pharmaceuticals's ISIN number?
Verrica Pharmaceuticals's international securities identification number is: US92511W1080 What is Verrica Pharmaceuticals's CUSIP number?
Verrica Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92511W108